Rapafusyn Research & Development, Inc.

BALTIMORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce an upcoming oral presentation at the 7th Targeted Protein Degradation & Induced Proximity Summit taking place from October 28-31, 2024 in Boston, MA. Dr. Rick Ewing, VP and Head of Chemistry, will be giving an oral presentation entitled “Non-Degrading Molecular Glues: A Platform for Finding Novel Chemical Matter for Inhibiting Intracellular & Transmembrane Proteins” on Oct 31st. Application of RapaGlues™ (Rapafusyn’s novel proximity inducing non-degrading macrocyclic molecular glues) and RapaTags™ (designed molecular glues) to deliver high quality HIT molecules will be presented. SAR campaigns will be described that have produced cell permeable molecules with extended PK half-life. “Our innovative non-degrading molecular glue platform has enabled significant advances in tackling difficult-to-drug targets. Rapafusyn’s platform is leveraging a modality validated by nature and extending it to broad types of disease targets. We are excited to share our progress at the 7th Targeted Protein Degradation & Induced Proximity Summit”, said Dr. Sean Hu, CEO of Rapafusyn. About Rapafusyn Pharmaceuticals At Rapafusyn, we’re creating non-degrading molecular glues to address hard-to-drug targets. Using our FKBP12-binding macrocyclic peptide platform, we've built large DNA encoded libraries (DELs) and arrayed libraries, yielding novel starting points. Our approach targets intracellular proteins and domains of transmembrane proteins like SLCs, ion channels, and GPCRs. With a modular design, we rapidly optimize key drug properties to accelerate drug-discovery. For more information, please visit https://www.rapafusyn.com/ or contact Heather Lavin at hlavin@rapafusyn.com

BALTIMORE, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a leader in the field of non-degrading molecular glues, is pleased to announce the upcoming presentation of preclinical in vivo data from its selective ENT1 inhibitor for Acute Kidney Injury (AKI) at the American Society for Nephrology (ASN) Kidney Week 2024 to be held from October 24-27, 2024, in San Diego, CA. Rapafusyn’s lead program, RAP-0001, is advancing rapidly to address a critical unmet need: the prevention of Acute Kidney Injury (AKI) in patients undergoing cardiac surgery. AKI is a severe and common complication, leading to prolonged hospital stays, increased morbidity, and higher mortality rates. With no approved therapies currently available, novel solutions are urgently needed. RAP-0001, a potent and selective inhibitor of the ENT1 transporter, has shown preclinical efficacy in preventing ischemia/reperfusion injury, a major driver of AKI. “This compound was discovered through the RapaGlue™ platform. As a molecular glue, RAP-0001 uniquely binds to the intracellular chaperone protein FKBP12 and ENT1 to form a ternary complex. To our knowledge, it’s the only SLC inhibitor that targets the intracellular domain of a transporter,” said Dr. Matthew Olson, VP of Biological Sciences of Rapafusyn, who will present in vivo data demonstrating RAP-0001’s ability to significantly reduce kidney damage in this high-risk context on October 25 th , 2024. Dr. Sean Hu, CEO of Rapafusyn, stated, “We believe RAP-0001 could change the standard of care for AKI, providing a critical therapeutic option where none currently exist. This is yet another example of recent developments demonstrating how non-degrading molecular glues could potentially tackle challenging disease targets and address high unmet medical needs in ways more effective than other drug modalities.” About Rapafusyn At Rapafusyn, we’re creating non-degrading molecular glues to address hard-to-drug targets. Using our FKBP12-binding macrocyclic peptide platform, we’ve built large DNA encoded libraries (DELs) and arrayed libraries, yielding novel starting points. Our approach targets intracellular proteins and domains of transmembrane proteins like SLCs, ion channels, and GPCRs. With a modular design, we rapidly optimize key drug properties to accelerate drug-discovery. For more information, please visit or contact Heather Lavin at hlavin@rapafusyn.com .

▎药明康德内容团队编辑 据创鉴汇不完全统计，上周（6月17日至6月23日）全球大健康领域共披露融资事件25起，总额超60亿元。按照金额划分，亿元及以上融资9起。按照已披露的融资轮次划分，早期融资（B轮以前）6起，中后期融资（B轮及以后）9起。生物医药领域共13家公司获融资，涉及药物类型包括分子胶药物、mRNA药物、创新肿瘤免疫抑制剂等。 #01 Marea Therapeutics完成1.9亿美元融资 关键词：心脏代谢疾病药物 最新融资：1.9亿美元A轮及B轮 本轮投资机构：Alpha Wave Global、Forbion、Omega Funds、Perceptive Xontogeny Venture Funds、Sofinnova等 6月19日，Marea Therapeutics宣布走出隐匿模式，并完成共1.9亿美元的A轮和B轮融资。Marea旨在开发用于治疗心脏代谢疾病的新一代药物，其用于降低残留胆固醇的潜在“first-in-class”主打项目MAR001目前正在2期试验受检视，这笔融资将用于资助该2期试验开发计划，以及其他管线项目的进一步推进。 Marea的主要项目MAR001是一种潜在"first-in-class"的单克隆抗体，靶向在脂肪组织中高度表达的ANGPTL4蛋白。MAR001通过抑制ANGPTL4，从而优先增强脂肪组织中的脂蛋白脂肪酶（LPL）活性，进而降低残留胆固醇，改善脂肪组织和代谢功能，并减少心血管事件。残留胆固醇由富含甘油三酯的脂蛋白所携带，会造成动脉粥样硬化，并在独立于传统风险因素（如低密度脂蛋白胆固醇、糖尿病或肥胖）下驱动心血管事件。目前尚无获批的靶向疗法来降低人体残留胆固醇的水平并改善代谢功能。 #02 iOnctura完成8000万欧元B轮融资 关键词：肿瘤免疫抑制剂 最新融资：8000万欧元B轮 本轮投资机构：3B Future Health Fund、European Innovation Council、INKEF Capital、M Ventures 、Schroders Capital等 6月20日，iOnctura宣布完成8000万欧元的B轮融资。iOnctur正在开发一系列精准口服小分子抗癌药物。该公司已将两种候选疗法推进到中期临床开发阶段。主打在研药物roginolisib是一款PI3Kδ别构调节剂，具有独特的化学结构和结合模式。新闻稿指出，roginolisib有潜力成为首个成功靶向PI3Kδ关键癌症通路的治疗方法。此次融资将用于加速roginolisib用于治疗葡萄膜黑色素瘤（UM）的临床试验，这是一种眼部罕见癌症，目前可用的治疗方法很少。在一项1b期临床试验中，roginolisib在UM中表现出长期安全性和可喜的疗效，且在数月内持续保持临床活性。 #03 Elion Therapeutics完成8100万美元B轮融资 关键词：抗侵袭性真菌感染药物 最新融资：8100万美元B轮 本轮投资机构：AMR Action Fund、Deerfield Management、Illinois Ventures 6月17日，生物技术公司Elion Therapeutics完成了由Deerfield Management和AMR Action Fund领投的8100万美元的B轮融资。该公司是致力于转变危及生命的侵袭性真菌感染（IFI）治疗方法的生物技术公司，主要研究方向是开发旨在降低毒性的下一代多烯抗真菌药物SF001。目前，SF001正在进行多次递增剂量研究，其活性分子是抗真菌药物两性霉素B的新型类似物，可减轻全身毒性。该轮融资资金将继续用于推进SF001的临床试验和研发。 #04 Iambic Therapeutics获得5000万美元融资 关键词：人工智能药物发现 最新融资：5000万美元B轮 本轮投资机构：Abingworth、Coatue Management、Exor Ventures、Illumina Ventures、Mubadala Capital 6月18日，Iambic Therapeutics宣布完成5000万美元的B轮扩展融资。获得资金将用于推进Iambic的临床期和临床前项目，包括IAM1363，一种高度选择性、可穿越血脑屏障的HER2抑制剂。它可以抑制野生型和携带致癌突变的HER2受体，目前处于1/1b期研究中。获得资金还将用于开发一种潜在“first-in-class”的CDK2/4抑制剂，旨在扩大治疗窗口并解决乳腺癌等实体瘤中的耐药问题。Iambic的候选药物是使用其AI蛋白结构预测和整体药物设计模型发现的。这些技术集成在一个闭环、自动化、高通量的生物和化学实验平台中，每周从数千种分子设计中提供新的生物学见解，从而直接为其AI模型提供信息。 #05 Rapafusyn获2800万美元A轮融资 关键词：非降解分子胶 最新融资：2800万美元A轮 本轮投资机构：本草资本、比邻星创投、龙磐资本 6月20日，瑞福信医药科技（Rapafusyn Pharmaceuticals，简称“瑞福信”或“Rapafusyn”）宣布完成A轮追加轮次融资的初步交割，A轮总融资额达2800万美元。Rapafusyn为基于非降解分子胶的创新药物发现及开发公司。本次融资将用于该公司基于大环环肽的非降解分子胶技术平台发展和针对广泛疾病种类的创新药管线推进，并进一步提升其内部新药研发能力。 Rapafusyn诞生于约翰·霍普金斯大学（Johns Hopkins University）药理学和分子科学教授刘钧（Jun O. Liu）博士的实验室，在2015年由刘钧教授和严圣军博士共同创建，是新一代双功能大环类药物研发平台公司，旨在开发非降解分子胶以解决难成药靶点的问题，改善患者治疗效果。 读者们请星标⭐创鉴汇，第一时间收到推送 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。 更多数据内容推荐 点击“在看”，分享创鉴汇健康新动态